Zhao Hongwei, Zhao Panpan, Huang Chao
School of Basic Medical Sciences, Department of Medicine, Kunming University of Science and Technology, Kunming, China.
Hum Cell. 2024 Sep;37(5):1347-1354. doi: 10.1007/s13577-024-01092-9. Epub 2024 Jun 10.
SUMOylation is a dynamic and reversible post-translational modification (PTM) of proteins involved in the regulation of biological processes such as protein homeostasis, DNA repair and cell cycle in normal and tumor cells. In particular, overexpression of SUMOylation components in tumor cells increases the activity of intracellular SUMOylation, protects target proteins against ubiquitination degradation and activation, promoting tumor cell proliferation and metastasis, providing immune evasion and increasing tolerance to chemotherapy and antitumor drugs. However, with the continuous research on SUMOylation and with the continued development of SUMOylation inhibitors, it has been found that tumor initiation and progression can be inhibited by blocking SUMOylation and/or in combination with drugs. SUMOylation is not a bad target when trying to treat tumor. This review introduces SUMOylation cycle pathway and summarizes the role of SUMOylation in tumor initiation and progression and SUMOylation inhibitors and their functions in tumors and provides a prospective view of SUMOylation as a new therapeutic target for tumors.
SUMO化是一种动态且可逆的蛋白质翻译后修饰(PTM),参与正常细胞和肿瘤细胞中生物过程的调控,如蛋白质稳态、DNA修复和细胞周期。特别是,肿瘤细胞中SUMO化成分的过表达会增加细胞内SUMO化的活性,保护靶蛋白免受泛素化降解和激活,促进肿瘤细胞增殖和转移,提供免疫逃逸并增加对化疗和抗肿瘤药物的耐受性。然而,随着对SUMO化研究的不断深入以及SUMO化抑制剂的不断发展,已发现通过阻断SUMO化和/或与药物联合使用可抑制肿瘤的发生和进展。在尝试治疗肿瘤时,SUMO化并非一个糟糕的靶点。本文综述了SUMO化循环途径,总结了SUMO化在肿瘤发生和进展中的作用、SUMO化抑制剂及其在肿瘤中的功能,并对SUMO化作为肿瘤新治疗靶点的前景进行了展望。